Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4000805 | Urologic Oncology: Seminars and Original Investigations | 2011 | 9 Pages |
Abstract
Recently, a large number of studies have shown that the addition of proton 1H-spectroscopic imaging (1H-MRSI) and dynamic contrast enhanced imaging (DCEMR) to magnetic resonance (MR) could represent a powerful tool for the management of prostate cancer (CaP) in most of its aspects. This combination of MR techniques can substantially sustain the clinical management of patients with CaP at different levels: in particular, (1) in the initial assessment, reducing the need for more extensive biopsies and directing targeted biopsies; (2) in the definition of a biochemical progression after primary therapies, distinguishing between fibrotic reaction and local recurrence from CaP.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia, Susanna Cattarino, Dino Lisi, Alessandro Gentilucci, Andrea Alfarone, Gianna Mariotti, Roberto Passariello, Vincenzo Gentile,